Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study
| Autor: | Poong-Lyul Rhee, Kyunga Kim, Jong Heon Park, Han Ho Jeon, Seungho Ryu, Hee Jung Son, Yeong Chan Lee, Yang Won Min, Kyoung Sub Hong, Yong Sung Kim |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Risk
medicine.medical_specialty medicine.drug_class Osteoporosis Proton-pump inhibitor Proton pump inhibitor Drug side effect Hip fracture Cohort Studies Population based cohort Risk Factors Internal medicine medicine Humans Hip Fractures business.industry Gastroenterology Proton Pump Inhibitors medicine.disease Confidence interval Relative risk Cohort Medicine Original Article business Body mass index |
| Zdroj: | The Korean Journal of Internal Medicine The Korean Journal of Internal Medicine, Vol 35, Iss 5, Pp 1084-1093 (2020) |
| ISSN: | 2005-6648 1226-3303 |
| DOI: | 10.3904/kjim.2018.331 |
| Popis: | Background/Aims Effect of proton pump inhibitor (PPI) use on the risk of hip fracture is controversial. This study aimed to clarify the association between PPI use and hip fracture risk using a large cohort. Methods This study recruited participants from the nationwide cohort (n = 1,025,340). After exclusion of participants who had hip fractures or were aged less than 40 years during the baseline period (2002 to 2004), 371,806 participants were followed to 2013. Participants prescribed PPIs for more than 90 days during baseline period were defined as users. Fracture cases were defined when participants were hospitalized with claims of a hip fracture. Results During 4,159,343 person-years of follow-up, fractures developed more often in PPI users than in nonusers (relative risk [RR], 1.787; 95% confidence interval [CI], 1.260 to 2.534; p = 0.002). The results persisted after adjusting for age, sex, and many drugs relevant to osteoporosis or influential in bone health. Furthermore, fracture risk associated with PPI use increased with duration of use (p trend < 0.001). The fully adjusted RRs of hip fracture development were 1.350 (95% CI, 1.203 to 1.515) for 1- to 90-day users, 1.487 (95% CI, 0.957 to 2.311) for 91- to 180-day users, and 1.771 (95% CI, 0.931 to 3.368) for > 180-day users. The positive association between PPI use and fracture was also confirmed in a subgroup with health screening data where further adjustment for body mass index, smoking status, alcohol consumption, and physical activity was available (adjusted RR, 2.025; 95% CI, 1.151 to 3.564, p = 0.014). Conclusions PPI use is associated with hip fracture development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|